Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Free Cash Flow (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Free Cash Flow for 16 consecutive years, with -$17.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 35.78% to -$17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$82.6 million through Dec 2025, down 349.85% year-over-year, with the annual reading at -$82.6 million for FY2025, 349.85% down from the prior year.
  • Free Cash Flow hit -$17.1 million in Q4 2025 for Perspective Therapeutics, up from -$23.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $13.8 million in Q1 2024 to a low of -$26.7 million in Q4 2024.
  • Historically, Free Cash Flow has averaged -$8.1 million across 5 years, with a median of -$7.9 million in 2023.
  • Biggest five-year swings in Free Cash Flow: soared 437.44% in 2021 and later crashed 584.41% in 2023.
  • Year by year, Free Cash Flow stood at $2.8 million in 2021, then crashed by 325.41% to -$6.2 million in 2022, then tumbled by 61.33% to -$10.1 million in 2023, then tumbled by 164.9% to -$26.7 million in 2024, then surged by 35.78% to -$17.1 million in 2025.
  • Business Quant data shows Free Cash Flow for CATX at -$17.1 million in Q4 2025, -$23.9 million in Q3 2025, and -$15.3 million in Q2 2025.